Targeting the DNA double strand breaks repair for cancer therapy

Current Medicinal Chemistry

Volumn 17, Issue 19, 2010, Pages 2017-2048

  Gullotta, Francesca ^a   de Marinis, Elisabetta ^a   Ascenzi, Paolo ^a,b   di Masi, Alessandra ^a  

^a ROMA TRE UNIVERSITY   (Italy)

^b NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

Author keywords

Cancer susceptibility; Cancer therapy; DNA damage response; DNA double strand breaks; DNA repair; Inhibitors of DNA repair

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; 2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 8 FLUORO 3,4 DIHYDRO 2 [4 (METHYLAMINOMETHYL)PHENYL]PYRROLO[3,4,5 E,F][2]BENZAZEPIN 6(5H) ONE; AMSACRINE; ANTINEOPLASTIC AGENT; ATM PROTEIN; ATR PROTEIN; BRCA1 PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; DNA DEPENDENT PROTEIN KINASE; DOUBLE STRANDED DNA; DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; HYMENIALDISINE; IC 87102; IC 87361; NU 7026; NU 7441; OK 1035; OLAPARIB; SALVICINE; SCHIZANDRIN B; SU 11752; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLIN; WORTMANNIN; CHROMATIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ARTICLE; BRCA 1 GENE; CANCER SUSCEPTIBILITY; CANCER THERAPY; CHROMATIN STRUCTURE; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; GENE; GENE FUNCTION; GENE MUTATION; GENOMIC INSTABILITY; HUMAN; NONHUMAN; PROTEIN FUNCTION; ANTAGONISTS AND INHIBITORS; CHEMISTRY; CHROMATIN; CLINICAL TRIAL (TOPIC); DNA DAMAGE; GENETICS; METABOLISM; NEOPLASMS;

BRCA1 PROTEIN; CHROMATIN; CLINICAL TRIALS AS TOPIC; DNA BREAKS, DOUBLE-STRANDED; DNA DAMAGE; DNA REPAIR; DNA REPAIR ENZYMES; ENZYME INHIBITORS; HUMANS; NEOPLASMS;

EID: 77953512068     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791233698     Document Type: Article

References (355)

1. Humpal, S.E.; Robinson, D.A.; Krebs, J.E. Marks to stop the clock: histone modifications and checkpoint regulation in the DNA damage response. Biochem. Cell Biol., 2009, 87, 243-53.
2. Kaufmann, W.K.; Paules, R.S. DNA damage and cell cycle check-points. FASEB J., 1996, 10, 238-47.
3. O'Driscoll, M.; Jeggo, P.A. The role of double-strand break repair -insights from human genetics. Nat. Rev. Genet., 2006, 7, 45-54.
4. Sancar, A.; Lindsey-Boltz, L.A.; Unsal-Kacmaz, K.; Linn, S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu. Rev. Biochem., 2004, 73, 39-85.
5. Madhusudan, S.; Middleton, M.R. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev., 2005, 31, 603-17.
6. Hoeijmakers, J.H. Genome maintenance mechanisms for preventing cancer. Nature, 2001, 411, 366-74.
7. di Masi, A.; Beradinelli, F.; Antoccia, A. In Genetic Inheritance Patterns; Ren Kimura, Ed.; Nova Science Publishers: Hauppauge NY, 2008; Vol. 21-73.
8. Bannon, J.H.; Mc Gee, M.M. Understanding the role of aneuploidy in tumorigenesis. Biochem. Soc. Trans., 2009, 37, 910-3.
9. Weaver, B.A.; Cleveland, D.W. Aneuploidy: instigator and inhibitor of tumorigenesis. Cancer Res., 2007, 67, 10103-5.
10. O'Driscoll, M.; Cerosaletti, K.M.; Girard, P.M.; Dai, Y.; Stumm, M.; Kysela, B.; Hirsch, B.; Gennery, A.; Palmer, S.E.; Seidel, J.; Gatti, R.A.; Varon, R.; Oettinger, M.A.; Neitzel, H.; Jeggo, P.A.; Concannon, P. DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol. Cell, 2001, 8, 1175-85.
11. Ben Omran, T.I.; Cerosaletti, K.; Concannon, P.; Weitzman, S.; Nezarati, M.M. A patient with mutations in DNA Ligase IV: clinical features and overlap with Nijmegen breakage syndrome. Am. J. Med. Genet. A, 2005, 137A, 283-7.
12. Altieri, F.; Grillo, C.; Maceroni, M.; Chichiarelli, S. DNA damage and repair: from molecular mechanisms to health implications. Antioxid. Redox. Signal., 2008, 10, 891-937.
13. Chistiakov, D.A.; Voronova, N.V.; Chistiakov, P.A. Genetic variations in DNA repair genes, radiosensitivity to cancer and susceptibility to acute tissue reactions in radiotherapy-treated cancer patients. Acta Oncol., 2008, 47, 809-24.
14. O'Driscoll, M.; Jeggo, P.A. The role of the DNA damage response pathways in brain development and microcephaly: insight from human disorders. DNA Repair (Amst), 2008, 7, 1039-50.
15. Bender, C.F.; Sikes, M.L.; Sullivan, R.; Huye, L.E.; Le Beau, M.M.; Roth, D.B.; Mirzoeva, O.K.; Oltz, E.M.; Petrini, J.H. Cancer predisposition and hematopoietic failure in Rad50(S/S) mice. Genes Dev., 2002, 16, 2237-51.
16. Ahmed, M.; Rahman, N. ATM and breast cancer susceptibility. Oncogene, 2006, 25, 5906-11.
17. Ralhan, R.; Kaur, J.; Kreienberg, R.; Wiesmuller, L. Links between DNA double strand break repair and breast cancer: accumulating evidence from both familial and nonfamilial cases. Cancer Lett., 2007, 248, 1-17.
18. di Masi, A.; Antoccia, A. NBS1 heterozygosity and cancer risk. Curr. Genom., 2008, 9, 275-81.
19. Powell, S.N.; Bindra, R.S. Targeting the DNA damage response for cancer therapy. DNA Repair (Amst), 2009, 8, 1153-65.
20. Schmith, V.D.; Campbell, D.A.; Sehgal, S.; Anderson, W.H.; Burns, D.K.; Middleton, L.T.; Roses, A.D. Pharmacogenetics and disease genetics of complex diseases. Cell Mol. Life Sci., 2003, 60, 1636-46.
21. Jeggo, P.A.; Lobrich, M. Contribution of DNA repair and cell cycle checkpoint arrest to the maintenance of genomic stability. DNA Repair (Amst), 2006, 5, 1192-8.
22. Shrivastav, M.; De Haro, L.P.; Nickoloff, J.A. Regulation of DNA double-strand break repair pathway choice. Cell Res., 2008, 18, 134-47.
23. Bernstein, K.A.; Rothstein, R. At loose ends: resecting a double-strand break. Cell, 2009, 137, 807-10.
24. Pardo, B.; Gomez-Gonzalez, B.; Aguilera, A. DNA repair in mammalian cells: DNA double-strand break repair: how to fix a broken relationship. Cell Mol. Life Sci., 2009, 66, 1039-56.
25. Jeggo, P.A.; Lobrich, M. DNA double-strand breaks: their cellular and clinical impact? Oncogene, 2007, 26, 7717-9.
26. Shin, D.S.; Chahwan, C.; Huffman, J.L.; Tainer, J.A. Structure and function of the double-strand break repair machinery. DNA Repair (Amst), 2004, 3, 863-73.
27. Mahaney, B.L.; Meek, K.; Lees-Miller, S.P. Repair of ionizing radiation-induced DNA double-strand breaks by non-homologous end-joining. Biochem. J., 2009, 417, 639-50.
28. Ward, J.F. The complexity of DNA damage: relevance to biological consequences. Int. J. Radiat. Biol., 1994, 66, 427-32.
29. van Gent, D.C.; Hoeijmakers, J.H.; Kanaar, R. Chromosomal stability and the DNA double-stranded break connection. Nat. Rev. Genet., 2001, 2, 196-206.
30. Povirk, L.F. Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks. DNA Repair (Amst), 2006, 5, 1199-212.
31. Natarajan, A.T.; Palitti, F. DNA repair and chromosomal alterations. Mutat. Res., 2008, 657, 3-7.
32. Pierce, A.J.; Stark, J.M.; Araujo, F.D.; Moynahan, M.E.; Berwick, M.; Jasin, M. Double-strand breaks and tumorigenesis. Trends Cell Biol., 2001, 11, S52-S59.
33. Sakata, K.; Someya, M.; Matsumoto, Y.; Hareyama, M. Ability to repair DNA double-strand breaks related to cancer susceptibility and radiosensitivity. Radiat. Med., 2007, 25, 433-8.
34. Paull, T.T.; Rogakou, E.P.; Yamazaki, V.; Kirchgessner, C.U.; Gellert, M.; Bonner, W.M. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr. Biol., 2000, 10, 886-95.
35. Rouse, J.; Jackson, S.P. Interfaces between the detection, signaling, and repair of DNA damage. Science, 2002, 297, 547-51.
36. Kobayashi, J.; Iwabuchi, K.; Miyagawa, K.; Sonoda, E.; Suzuki, K.; Takata, M.; Tauchi, H. Current topics in DNA double-strand break repair. J. Radiat. Res. (Tokyo), 2008, 49, 93-103.
37. Stewart, G.S.; Wang, B.; Bignell, C.R.; Taylor, A.M.; Elledge, S.J. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature, 2003, 421, 961-6.
38. Rai, R.; Dai, H.; Multani, A.S.; Li, K.; Chin, K.; Gray, J.; Lahad, J.P.; Liang, J.; Mills, G.B.; Meric-Bernstam, F.; Lin, S.Y. BRIT1 regulates early DNA damage response, chromosomal integrity, and cancer. Cancer Cell, 2006, 10, 145-57.
39. Petrini, J.H.; Stracker, T.H. The cellular response to DNA double-strand breaks: defining the sensors and mediators. Trends Cell Biol., 2003, 13, 458-62.
40. Kuo, L.J.; Yang, L.X. Gamma-H2AX - a novel biomarker for DNA double-strand breaks. In Vivo, 2008, 22, 305-9.
41. Rogakou, E.P.; Boon, C.; Redon, C.; Bonner, W.M. Megabase chromatin domains involved in DNA double-strand breaks in vivo. J. Cell Biol., 1999, 146, 905-16.
42. Shroff, R.; Arbel-Eden, A.; Pilch, D.; Ira, G.; Bonner, W.M.; Petrini, J.H.; Haber, J.E.; Lichten, M. Distribution and dynamics of chromatin modification induced by a defined DNA double-strand break. Curr. Biol., 2004, 14, 1703-11.
43. Berkovich, E.; Monnat, R.J., Jr.; Kastan, M.B. Roles of ATM and NBS1 in chromatin structure modulation and DNA double-strand break repair. Nat. Cell Biol., 2007, 9, 683-90.
44. Scully, R.; Chen, J.; Ochs, R.L.; Keegan, K.; Hoekstra, M.; Feunteun, J.; Livingston, D.M. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. Cell, 1997, 90, 425-35.
45. Carney, J.P.; Maser, R.S.; Olivares, H.; Davis, E.M.; Le Beau, M.; Yates, J.R., III; Hays, L.; Morgan, W.F.; Petrini, J.H. The hMre11/hRad50 protein complex and Nijmegen breakage syndrome: linkage of double-strand break repair to the cellular DNA damage response. Cell, 1998, 93, 477-86.
46. Zhong, Q.; Chen, C.F.; Li, S.; Chen, Y.; Wang, C.C.; Xiao, J.; Chen, P.L.; Sharp, Z.D.; Lee, W.H. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science, 1999, 285, 747-50.
47. Rappold, I.; Iwabuchi, K.; Date, T.; Chen, J. Tumor suppressor p53 binding protein 1 (53BP1) is involved in DNA damage-signaling pathways. J. Cell Biol., 2001, 153, 613-20.
48. Celeste, A.; Petersen, S.; Romanienko, P.J.; Fernandez-Capetillo, O.; Chen, H.T.; Sedelnikova, O.A.; Reina-San-Martin, B.; Coppola, V.; Meffre, E.; Difilippantonio, M.J.; Redon, C.; Pilch, D.R.; Olaru, A.; Eckhaus, M.; Camerini-Otero, R.D.; Tessarollo, L.; Livak, F.; Manova, K.; Bonner, W.M.; Nussenzweig, M.C.; Nussenzweig, A. Genomic instability in mice lacking histone H2AX. Science, 2002, 296, 922-7.
49. Goldberg, M.; Stucki, M.; Falck, J.; D'Amours, D.; Rahman, D.; Pappin, D.; Bartek, J.; Jackson, S.P. MDC1 is required for the intra-S-phase DNA damage checkpoint. Nature, 2003, 421, 952-6.
50. van den, B.M.; Bree, R.T.; Lowndes, N.F. The MRN complex: coordinating and mediating the response to broken chromosomes. EMBO Rep., 2003, 4, 844-9.
51. Xu, X.; Stern, D.F. NFBD1/MDC1 regulates ionizing radiation-induced focus formation by DNA checkpoint signaling and repair factors. FASEB J., 2003, 17, 1842-8.
52. Lisby, M.; Rothstein, R. DNA damage checkpoint and repair centers. Curr. Opin. Cell Biol., 2004, 16, 328-34.
53. Helmink, B.A.; Bredemeyer, A.L.; Lee, B.S.; Huang, C.Y.; Sharma, G.G.; Walker, L.M.; Bednarski, J.J.; Lee, W.L.; Pandita, T.K.; Bassing, C.H.; Sleckman, B.P. MRN complex function in the repair of chromosomal Rag-mediated DNA double-strand breaks. J. Exp. Med., 2009, 206, 669-79.
54. Porter-Goff, M.E.; Rhind, N. The role of MRN in the S-phase DNA damage checkpoint is independent of its Ctp1-dependent roles in double-strand break repair and checkpoint signaling. Mol. Biol. Cell, 2009, 20, 2096-107.
55. Shikazono, N.; Noguchi, M.; Fujii, K.; Urushibara, A.; Yokoya, A. The yield, processing, and biological consequences of clustered DNA damage induced by ionizing radiation. J. Radiat. Res. (Tokyo), 2009, 50, 27-36.
56. Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature, 2003, 421, 499-506.
57. Kitagawa, R.; Bakkenist, C.J.; McKinnon, P.J.; Kastan, M.B. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev., 2004, 18, 1423-38.
58. Lowndes, N.F.; Murguia, J.R. Sensing and responding to DNA damage. Curr. Opin. Genet. Dev., 2000, 10, 17-25.
59. Sionov, R.V.; Haupt, Y. The cellular response to p53: the decision between life and death. Oncogene, 1999, 18, 6145-57.
60. Vakifahmetoglu, H.; Olsson, M.; Zhivotovsky, B. Death through a tragedy: mitotic catastrophe. Cell Death Differ., 2008, 15, 1153-62.
61. Frosina, G. DNA repair and resistance of gliomas to chemotherapy and radiotherapy. Mol. Cancer Res., 2009, 7, 989-99.
62. Chang, B.D.; Watanabe, K.; Broude, E.V.; Fang, J.; Poole, J.C.; Kalinichenko, T.V.; Roninson, I.B. Effects of p21Waf1/Cip1/Sdi1 on cellular gene expression: implications for carcinogenesis, senescence, and age-related diseases. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 4291-6.
63. Bartkova, J.; Horejsi, Z.; Koed, K.; Kramer, A.; Tort, F.; Zieger, K.; Guldberg, P.; Sehested, M.; Nesland, J.M.; Lukas, C.; Orntoft, T.; Lukas, J.; Bartek, J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature, 2005, 434, 864-70.
64. Celeste, A.; Difilippantonio, S.; Difilippantonio, M.J.; Fernandez-Capetillo, O.; Pilch, D.R.; Sedelnikova, O.A.; Eckhaus, M.; Ried, T.; Bonner, W.M.; Nussenzweig, A. H2AX haploinsufficiency modifies genomic stability and tumor susceptibility. Cell, 2003, 114, 371-83.
65. Difilippantonio, S.; Celeste, A.; Fernandez-Capetillo, O.; Chen, H.T.; Reina, S.M.; Van Laethem, F.; Yang, Y.P.; Petukhova, G.V.; Eckhaus, M.; Feigenbaum, L.; Manova, K.; Kruhlak, M.; Camerini-Otero, R.D.; Sharan, S.; Nussenzweig, M.; Nussenzweig, A. Role of Nbs1 in the activation of the Atm kinase revealed in humanized mouse models. Nat. Cell Biol., 2005, 7, 675-85.
66. Kanaar, R.; Hoeijmakers, J.H.; van Gent, D.C. Molecular mechanisms of DNA double strand break repair. Trends Cell Biol., 1998, 8, 483-9.
67. Lieber, M.R.; Ma, Y.; Pannicke, U.; Schwarz, K. Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell Biol., 2003, 4, 712-20.
68. Pierce, A.J.; Jasin, M. NHEJ deficiency and disease. Mol. Cell, 2001, 8, 1160-1.
69. Rothkamm, K.; Kruger, I.; Thompson, L.H.; Lobrich, M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol. Cell Biol., 2003, 23, 5706-15.
70. Thompson, L.H.; Schild, D. The contribution of homologous recombination in preserving genome integrity in mammalian cells. Biochimie, 1999, 81, 87-105.
71. Haber, J.E. Partners and pathwaysrepairing a double-strand break. Trends Genet., 2000, 16, 259-64.
72. Thompson, L.H.; Schild, D. Homologous recombinational repair of DNA ensures mammalian chromosome stability. Mutat. Res., 2001, 477, 131-53.
73. Golub, E.I.; Gupta, R.C.; Haaf, T.; Wold, M.S.; Radding, C.M. Interaction of human rad51 recombination protein with single-stranded DNA binding protein, RPA. Nucleic Acids Res., 1998, 26, 5388-93.
74. Sigurdsson, S.; Trujillo, K.; Song, B.; Stratton, S.; Sung, P. Basis for avid homologous DNA strand exchange by human Rad51 and RPA. J. Biol. Chem., 2001, 276, 8798-806.
75. Wyman, C.; Kanaar, R. Homologous recombination: down to the wire. Curr. Biol., 2004, 14, R629-R631.
76. Johnson, R.D.; Jasin, M. Sister chromatid gene conversion is a prominent double-strand break repair pathway in mammalian cells. EMBO J., 2000, 19, 3398-407.
77. Dvir, A.; Peterson, S.R.; Knuth, M.W.; Lu, H.; Dynan, W.S. Kuautoantigen is the regulatory component of a template-associated protein kinase that phosphorylates RNA polymerase II. Proc. Natl. Acad. Sci. U.S.A., 1992, 89, 11920-4.
78. Smith, G.C.; Jackson, S.P. The DNA-dependent protein kinase. Genes Dev., 1999, 13, 916-34.
79. Jackson, S.P. Sensing and repairing DNA double-strand breaks. Carcinogenesis, 2002, 23, 687-96.
80. Weterings, E.; van Gent, D.C. The mechanism of non-homologous end-joining: a synopsis of synapsis. DNA Repair (Amst), 2004, 3, 1425-35.
81. Moshous, D.; Callebaut, I.; de Chasseval, R.; Corneo, B.; Cavazzana-Calvo, M.; Le Deist, F.; Tezcan, I.; Sanal, O.; Bertrand, Y.; Philippe, N.; Fischer, A.; de Villartay, J.P. Artemis, a novel DNA double-strand break repair/V(D)J recombination protein, is mutated in human severe combined immune deficiency. Cell, 2001, 105, 177-86.
82. Riballo, E.; Kuhne, M.; Rief, N.; Doherty, A.; Smith, G.C.; Recio, M.J.; Reis, C.; Dahm, K.; Fricke, A.; Krempler, A.; Parker, A.R.; Jackson, S.P.; Gennery, A.; Jeggo, P.A.; Lobrich, M. A pathway of double-strand break rejoining dependent upon ATM, Artemis, and proteins locating to gamma-H2AX foci. Mol. Cell, 2004, 16, 715-24.
83. Zhang, X.; Succi, J.; Feng, Z.; Prithivirajsingh, S.; Story, M.D.; Legerski, R.J. Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. Mol. Cell Biol., 2004, 24, 9207-20.
84. Ahnesorg, P.; Smith, P.; Jackson, S.P. XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining. Cell, 2006, 124, 301-13.
85. Buck, D.; Malivert, L.; de Chasseval, R.; Barraud, A.; Fondaneche, M.C.; Sanal, O.; Plebani, A.; Stephan, J.L.; Hufnagel, M.; Le Deist, F.; Fischer, A.; Durandy, A.; de Villartay, J.P.; Revy, P. Cernunnos, a novel nonhomologous end-joining factor, is mutated in human immunodeficiency with microcephaly. Cell, 2006, 124, 287-99.
86. Callebaut, I.; Malivert, L.; Fischer, A.; Mornon, J.P.; Revy, P.; de Villartay, J.P. Cernunnos interacts with the XRCC4 x DNA-ligase IV complex and is homologous to the yeast nonhomologous end-joining factor Nej1. J. Biol. Chem., 2006, 281, 13857-60.
87. Critchlow, S.E.; Bowater, R.P.; Jackson, S.P. Mammalian DNA double-strand break repair protein XRCC4 interacts with DNA ligase IV. Curr. Biol., 1997, 7, 588-98.
88. Grawunder, U.; Wilm, M.; Wu, X.; Kulesza, P.; Wilson, T.E.; Mann, M.; Lieber, M.R. Activity of DNA ligase IV stimulated by complex formation with XRCC4 protein in mammalian cells. Nature, 1997, 388, 492-5.
89. Chen, L.; Trujillo, K.; Sung, P.; Tomkinson, A.E. Interactions of the DNA ligase IV-XRCC4 complex with DNA ends and the DNA-dependent protein kinase. J. Biol. Chem., 2000, 275, 26196-205.
90. Frank, K.M.; Sharpless, N.E.; Gao, Y.; Sekiguchi, J.M.; Ferguson, D.O.; Zhu, C.; Manis, J.P.; Horner, J.; DePinho, R.A.; Alt, F.W. DNA ligase IV deficiency in mice leads to defective neurogenesis and embryonic lethality via the p53 pathway. Mol. Cell, 2000, 5, 993-1002.
91. Kurimasa, A.; Kumano, S.; Boubnov, N.V.; Story, M.D.; Tung, C.S.; Peterson, S.R.; Chen, D.J. Requirement for the kinase activity of human DNA-dependent protein kinase catalytic subunit in DNA strand break rejoining. Mol. Cell Biol., 1999, 19, 3877-84.
92. Riballo, E.; Critchlow, S.E.; Teo, S.H.; Doherty, A.J.; Priestley, A.; Broughton, B.; Kysela, B.; Beamish, H.; Plowman, N.; Arlett, C.F.; Lehmann, A.R.; Jackson, S.P.; Jeggo, P.A. Identification of a defect in DNA ligase IV in a radiosensitive leukaemia patient. Curr. Biol., 1999, 9, 699-702.
93. Wachsberger, P.R.; Li, W.H.; Guo, M.; Chen, D.; Cheong, N.; Ling, C.C.; Li, G.; Iliakis, G. Rejoining of DNA double-strand breaks in Ku80-deficient mouse fibroblasts. Radiat. Res., 1999, 151, 398-407.
94. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128, 693-705.
95. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature, 2000, 403, 41-5.
96. Taverna, S.D.; Li, H.; Ruthenburg, A.J.; Allis, C.D.; Patel, D.J. How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers. Nat. Struct. Mol. Biol., 2007, 14, 1025-40.
97. Cairns, B.R.; Lorch, Y.; Li, Y.; Zhang, M.; Lacomis, L.; Erdjument-Bromage, H.; Tempst, P.; Du, J.; Laurent, B.; Kornberg, R.D. RSC, an essential, abundant chromatin-remodeling complex. Cell, 1996, 87, 1249-60.
98. Ikura, T.; Ogryzko, V.V.; Grigoriev, M.; Groisman, R.; Wang, J.; Horikoshi, M.; Scully, R.; Qin, J.; Nakatani, Y. Involvement of the TIP60 histone acetylase complex in DNA repair and apoptosis. Cell, 2000, 102, 463-73.
99. Symington, L.S. Role of RAD52 epistasis group genes in homologous recombination and double-strand break repair. Microbiol. Mol. Biol. Rev., 2002, 66, 630-70.
100. Cai, S.; Han, H.J.; Kohwi-Shigematsu, T. Tissue-specific nuclear architecture and gene expression regulated by SATB1. Nat. Genet., 2003, 34, 42-51.
101. Mizuguchi, G.; Shen, X.; Landry, J.; Wu, W.H.; Sen, S.; Wu, C. ATP-driven exchange of histone H2AZ variant catalyzed by SWR1 chromatin remodeling complex. Science, 2004, 303, 343-8.
102. Mohrmann, L.; Verrijzer, C.P. Composition and functional specificity of SWI2/SNF2 class chromatin remodeling complexes. Biochim. Biophys. Acta, 2005, 1681, 59-73.
103. Thoma, N.H.; Czyzewski, B.K.; Alexeev, A.A.; Mazin, A.V.; Kowalczykowski, S.C.; Pavletich, N.P. Structure of the SWI2/SNF2 chromatin-remodeling domain of eukaryotic Rad54. Nat. Struct. Mol. Biol., 2005, 12, 350-6.
104. Osley, M.A.; Shen, X. Altering nucleosomes during DNA double-strand break repair in yeast. Trends Genet., 2006, 22, 671-7.
105. Spotswood, H.T.; Turner, B.M. An increasingly complex code. J. Clin. Invest, 2002, 110, 577-82.
106. Fernandez-Capetillo, O.; Nussenzweig, A. Linking histone deacetylation with the repair of DNA breaks. Proc. Natl. Acad. Sci. U. S. A, 2004, 101, 1427-8.
107. Narlikar, G.J.; Fan, H.Y.; Kingston, R.E. Cooperation between complexes that regulate chromatin structure and transcription. Cell, 2002, 108, 475-87.
108. Costelloe, T.; Fitzgerald, J.; Murphy, N.J.; Flaus, A.; Lowndes, N.F. Chromatin modulation and the DNA damage response. Exp. Cell Res., 2006, 312, 2677-86.
109. Murr, R.; Loizou, J.I.; Yang, Y.G.; Cuenin, C.; Li, H.; Wang, Z.Q.; Herceg, Z. Histone acetylation by Trrap-Tip60 modulates loading of repair proteins and repair of DNA double-strand breaks. Nat. Cell Biol., 2006, 8, 91-9.
110. Squatrito, M.; Gorrini, C.; Amati, B. Tip60 in DNA damage response and growth control: many tricks in one HAT. Trends Cell Biol., 2006, 16, 433-42.
111. Sun, Y.; Jiang, X.; Chen, S.; Fernandes, N.; Price, B.D. A role for the Tip60 histone acetyltransferase in the acetylation and activation of ATM. Proc. Natl. Acad. Sci. U.S.A., 2005, 102, 13182-7.
112. Robert, F.; Hardy, S.; Nagy, Z.; Baldeyron, C.; Murr, R.; Dery, U.; Masson, J.Y.; Papadopoulo, D.; Herceg, Z.; Tora, L. The transcriptional histone acetyltransferase cofactor TRRAP associates with the MRN repair complex and plays a role in DNA double-strand break repair. Mol. Cell Biol., 2006, 26, 402-12.
113. Downey, M.; Durocher, D. Chromatin and DNA repair: the benefits of relaxation. Nat. Cell Biol., 2006, 8, 9-10.
114. Tsukuda, T.; Fleming, A.B.; Nickoloff, J.A.; Osley, M.A. Chromatin remodelling at a DNA double-strand break site in Saccharomyces cerevisiae. Nature, 2005, 438, 379-83.
115. Ausio, J.; Levin, D.B.; De Amorim, G.V.; Bakker, S.; Macleod, P.M. Syndromes of disordered chromatin remodeling. Clin. Genet., 2003, 64, 83-95.
116. Cho, B.P. Dynamic conformational heterogeneities of carcinogen-DNA adducts and their mutagenic relevance. J. Environ. Sci. Health C. Environ. Carcinog. Ecotoxicol. Rev., 2004, 22, 57-90.
117. Miki, Y.; Swensen, J.; Shattuck-Eidens, D.; Futreal, P.A.; Harshman, K.; Tavtigian, S.; Liu, Q.; Cochran, C.; Bennett, L.M.; Ding, W.;. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science, 1994, 266, 66-71.
118. Liede, A.; Karlan, B.Y.; Narod, S.A. Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: A review of the literature. J. Clin. Oncol., 2004, 22, 735-42.
119. Hemminki, K.; Bermejo, J.L. Effects of screening for breast cancer on its age-incidence relationships and familial risk. Int. J. Cancer, 2005, 117, 145-9.
120. Scully, R.; Chen, J.J.; Plug, A.; Xiao, Y.H.; Weaver, D.; Feunteun, J.; Ashley, T.; Livingston, D.M. Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell, 1997, 88, 265-75.
121. Wang, Y.; Cortez, D.; Yazdi, P.; Neff, N.; Elledge, S.J.; Qin, J. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. Genes Dev., 2000, 14, 927-39.
122. Baumann, P.; West, S.C. Role of the human RAD51 protein in homologous recombination and double-stranded break repair. Trends Biochem. Sci., 1998, 23, 247-51.
123. Gowen, L.C.; Avrutskaya, A.V.; Latour, A.M.; Koller, B.H.; Leadon, S.A. BRCA1 required for transcription-coupled repair of oxidative DNA damage (Retracted article. See vol 300, pg 1657, June 13 2003). Science, 1998, 281, 1009-12.
124. Abbott, D.W.; Thompson, M.E.; Robinson-Benion, C.; Tomlinson, G.; Jensen, R.A.; Holt, J.T. BRCA1 expression restores radiation resistance in BRCA1-defective cancer cells through enhancement of transcription-coupled DNA repair. J. Biol. Chem., 1999, 274, 18808-12.
125. Chen, Y.; Chen, C.F.; Riley, D.J.; Allred, D.C.; Chen, P.L.; Von Hoff, D.; Osborne, C.K.; Lee, W.H. Aberrant subcellular localization of BRCA1 in breast cancer. Science, 1995, 270, 789-91.
126. Scully, R.; Ganesan, S.; Brown, M.; De Caprio, J.A.; Cannistra, S.A.; Feunteun, J.; Schnitt, S.; Livingston, D.M. Location of BRCA1 in human breast and ovarian cancer cells. Science, 1996, 272, 123-6.
127. Chen, C.F.; Li, S.; Chen, Y.; Chen, P.L.; Sharp, Z.D.; Lee, W.H. The nuclear localization sequences of the BRCA1 protein interact with the importin-alpha subunit of the nuclear transport signal receptor. J. Biol. Chem., 1996, 271, 32863-8.
128. Koonin, E.V.; Tatusov, R.L.; Rudd, K.E. Protein sequence comparison at genome scale. Methods Enzymol., 1996, 266, 295-322.
129. Bork, P.; Hofmann, K.; Bucher, P.; Neuwald, A.F.; Altschul, S.F.; Koonin, E.V. A superfamily of conserved domains in DNA damage-responsive cell cycle checkpoint proteins. FASEB J., 1997, 11, 68-76.
130. Callebaut, I.; Mornon, J.P. From BRCA1 to RAP1: a widespread BRCT module closely associated with DNA repair. FEBS Lett., 1997, 400, 25-30.
131. Koonin, E.V.; Altschul, S.F.; Bork, P. BRCA1 protein products... Functional motifs. Nat. Genet., 1996, 13, 266-8.
132. Glover, J.N.; Williams, R.S.; Lee, M.S. Interactions between BRCT repeats and phosphoproteins: tangled up in two. Trends Biochem. Sci., 2004, 29, 579-85.
133. Williams, R.S.; Lee, M.S.; Hau, D.D.; Glover, J.N. Structural basis of phosphopeptide recognition by the BRCT domain of BRCA1. Nat. Struct. Mol. Biol., 2004, 11, 519-25.
134. Scully, R.; Puget, N.; Vlasakova, K. DNA polymerase stalling, sister chromatid recombination and the BRCA genes. Oncogene, 2000, 19, 6176-83.
135. Boulton, S.J. Cellular functions of the BRCA tumour-suppressor proteins. Biochem. Soc. Trans., 2006, 34, 633-45.
136. Deng, C.X.; Brodie, S.G. Roles of BRCA1 and its interacting proteins. Bioessays, 2000, 22, 728-37.
137. Wu, L.C.; Wang, Z.W.; Tsan, J.T.; Spillman, M.A.; Phung, A.; Xu, X.L.; Yang, M.C.; Hwang, L.Y.; Bowcock, A.M.; Baer, R. Identification of a RING protein that can interact in vivo with the BRCA1 gene product. Nat. Genet., 1996, 14, 430-40.
138. Jensen, D.E.; Proctor, M.; Marquis, S.T.; Gardner, H.P.; Ha, S.I.; Chodosh, L.A.; Ishov, A.M.; Tommerup, N.; Vissing, H.; Sekido, Y.; Minna, J.; Borodovsky, A.; Schultz, D.C.; Wilkinson, K.D.; Maul, G.G.; Barlev, N.; Berger, S.L.; Prendergast, G.C.; Rauscher, F.J., III BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. Oncogene, 1998, 16, 1097-112.
139. Chai, Y.L.; Cui, J.; Shao, N.; Shyam, E.; Reddy, P.; Rao, V.N. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. Oncogene, 1999, 18, 263-8.
140. Aprelikova, O.N.; Fang, B.S.; Meissner, E.G.; Cotter, S.; Campbell, M.; Kuthiala, A.; Bessho, M.; Jensen, R.A.; Liu, E.T. BRCA1-associated growth arrest is RB-dependent. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 11866-71.
141. Wong, A.K.; Ormonde, P.A.; Pero, R.; Chen, Y.; Lian, L.; Salada, G.; Berry, S.; Lawrence, Q.; Dayananth, P.; Ha, P.; Tavtigian, S.V.; Teng, D.H.; Bartel, P.L. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene, 1998, 17, 2279-85.
142. Yu, X.; Wu, L.C.; Bowcock, A.M.; Aronheim, A.; Baer, R. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem., 1998, 273, 25388-92.
143. Scully, R.; Anderson, S.F.; Chao, D.M.; Wei, W.; Ye, L.; Young, R.A.; Livingston, D.M.; Parvin, J.D. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc. Natl. Acad. Sci. U. S. A, 1997, 94, 5605-10.
144. Anderson, S.F.; Schlegel, B.P.; Nakajima, T.; Wolpin, E.S.; Parvin, J.D. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nat. Genet., 1998, 19, 254-6.
145. Yarden, R.I.;Brody, L.C. BRCA1 interacts with components of the histone deacetylase complex. Proc. Natl. Acad. Sci. U.S.A., 1999, 96, 4983-8.
146. Cantor, S.B.; Bell, D.W.; Ganesan, S.; Kass, E.M.; Drapkin, R.; Grossman, S.; Wahrer, D.C.; Sgroi, D.C.; Lane, W.S.; Haber, D.A.; Livingston, D.M. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. Cell, 2001, 105, 149-60.
147. Bochar, D.A.; Wang, L.; Beniya, H.; Kinev, A.; Xue, Y.; Lane, W.S.; Wang, W.; Kashanchi, F.; Shiekhattar, R. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 2000, 102, 257-65.
148. Hurley, P.J.; Bunz, F. ATM and ATR: components of an integrated circuit. Cell Cycle, 2007, 6, 414-7.
149. Hartman, A.R.;Ford, J.M. BRCA1 induces DNA damage recognition factors and enhances nucleotide excision repair. Nat. Genet., 2002, 32, 180-4.
150. Greenberg, R.A.; Sobhian, B.; Pathania, S.; Cantor, S.B.; Nakatani, Y.; Livingston, D.M. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev., 2006, 20, 34-46.
151. Polanowska, J.; Martin, J.S.; Garcia-Muse, T.; Petalcorin, M.I.; Boulton, S.J. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. EMBO J., 2006, 25, 2178-88.
152. Somasundaram, K.; Zhang, H.; Zeng, Y.X.; Houvras, Y.; Peng, Y.; Zhang, H.; Wu, G.S.; Licht, J.D.; Weber, B.L.; El Deiry, W.S. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. Nature, 1997, 389, 187-90.
153. Ouchi, T.; Monteiro, A.N.; August, A.; Aaronson, S.A.; Hanafusa, H. BRCA1 regulates p53-dependent gene expression. Proc. Natl. Acad. Sci. U. S. A, 1998, 95, 2302-6.
154. Xu, X.; Qiao, W.; Linke, S.P.; Cao, L.; Li, W.M.; Furth, P.A.; Harris, C.C.; Deng, C.X. Genetic interactions between tumor suppressors Brca1 and p53 in apoptosis, cell cycle and tumorigenesis. Nat. Genet., 2001, 28, 266-71.
155. Xu, X.; Wagner, K.U.; Larson, D.; Weaver, Z.; Li, C.; Ried, T.; Hennighausen, L.; Wynshaw-Boris, A.; Deng, C.X. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet., 1999, 22, 37-43.
156. Xu, X.; Weaver, Z.; Linke, S.P.; Li, C.; Gotay, J.; Wang, X.W.; Harris, C.C.; Ried, T.; Deng, C.X. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol. Cell, 1999, 3, 389-95.
157. Glover, J.N. Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam. Cancer, 2006, 5, 89-93.
158. Breast Cancer Information Core. Available at http://research.nhgri.nih.gov/bic/. Accessed on October 2009.
159. Goldgar, D.E.; Easton, D.F.; Deffenbaugh, A.M.; Monteiro, A.N.; Tavtigian, S.V.; Couch, F.J. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet., 2004, 75, 535-44.
160. Szabo, C.I.; Schutte, M.; Broeks, A.; Houwing-Duistermaat, J.J.; Thorstenson, Y.R.; Durocher, F.; Oldenburg, R.A.; Wasielewski, M.; Odefrey, F.; Thompson, D.; Floore, A.N.; Kraan, J.; Klijn, J.G.; van den Ouweland, A.M.; Wagner, T.M.; Devilee, P.; Simard, J.; 't Veer, L.J.; Goldgar, D.E.; Meijers-Heijboer, H. Are ATM mutations 7271T-->G and IVS10-6T-->G really high-risk breast cancer-susceptibility alleles? Cancer Res., 2004, 64, 840-3.
161. Easton, D.F.; Deffenbaugh, A.M.; Pruss, D.; Frye, C.; Wenstrup, R.J.; Allen-Brady, K.; Tavtigian, S.V.; Monteiro, A.N.; Iversen, E.S.; Couch, F.J.; Goldgar, D.E. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am. J. Hum. Genet., 2007, 81, 873-83.
162. Williams, R.S.;Glover, J.N. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. J. Biol. Chem., 2003, 278, 2630-5.
163. Mirkovic, N.; Marti-Renom, M.A.; Weber, B.L.; Sali, A.; Monteiro, A.N. Structure-based assessment of missense mutations in human BRCA1: implications for breast and ovarian cancer predisposition. Cancer Res., 2004, 64, 3790-7.
164. Carvalho, M.A.; Marsillac, S.M.; Karchin, R.; Manoukian, S.; Grist, S.; Swaby, R.F.; Urmenyi, T.P.; Rondinelli, E.; Silva, R.; Gayol, L.; Baumbach, L.; Sutphen, R.; Pickard-Brzosowicz, J.L.; Nathanson, K.L.; Sali, A.; Goldgar, D.; Couch, F.J.; Radice, P.; Monteiro, A.N. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res., 2007, 67, 1494-501.
165. Karchin, R.; Monteiro, A.N.; Tavtigian, S.V.; Carvalho, M.A.; Sali, A. Functional impact of missense variants in BRCA1 predicted by supervised learning. PLoS Comput. Biol., 2007, 3, e26.
166. Domchek, S.; Weber, B.L. Genetic variants of uncertain significance: flies in the ointment. J. Clin. Oncol., 2008, 26, 16-7.
167. Carvalho, M.A.; Couch, F.J.; Monteiro, A.N. Functional assays for BRCA1 and BRCA2. Int. J. Biochem. Cell Biol., 2007, 39, 298-310.
168. Vallon-Christersson, J.; Cayanan, C.; Haraldsson, K.; Loman, N.; Bergthorsson, J.T.; Brondum-Nielsen, K.; Gerdes, A.M.; Moller, P.; Kristoffersson, U.; Olsson, H.; Borg, A.; Monteiro, A.N. Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families. Hum. Mol. Genet., 2001, 10, 353-60.
169. Williams, R.S.; Bernstein, N.; Lee, M.S.; Rakovszky, M.L.; Cui, D.; Green, R.; Weinfeld, M.; Glover, J.N. Structural basis for phosphorylation-dependent signaling in the DNA-damage response. Biochem. Cell Biol., 2005, 83, 721-7.
170. Zhou, B.B.; Bartek, J. Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat. Rev. Cancer, 2004, 4, 216-25.
171. Longley, D.B.; Johnston, P.G. Molecular mechanisms of drug resistance. J. Pathol., 2005, 205, 275-92.
172. Martin, S.A.; Lord, C.J.; Ashworth, A. DNA repair deficiency as a therapeutic target in cancer. Curr. Opin. Genet. Dev., 2008, 18, 80-6.
173. Madhusudan, S.; Hickson, I.D. DNA repair inhibition: a selective tumour targeting strategy. Trends Mol. Med., 2005, 11, 503-11.
174. Belzile, J.P.; Choudhury, S.A.; Cournoyer, D.; Chow, T.Y. Targeting DNA repair proteins: a promising avenue for cancer gene therapy. Curr. Gene Ther., 2006, 6, 111-23.
175. Ding, J.; Miao, Z.H.; Meng, L.H.; Geng, M.Y. Emerging cancer therapeutic opportunities target DNA-repair systems. Trends Pharmacol. Sci., 2006, 27, 338-44.
176. O'Connor, M.J.; Martin, N.M.; Smith, G.C. Targeted cancer therapies based on the inhibition of DNA strand break repair. Oncogene, 2007, 26, 7816-24.
177. Kelley, M.R.; Fishel, M.L. DNA repair proteins as molecular targets for cancer therapeutics. Anticancer Agents Med. Chem., 2008, 8, 417-25.
178. Kinsella, T.J. Understanding DNA damage response and DNA repair pathways: applications to more targeted cancer therapeutics. Semin. Oncol., 2009, 36, S42-S51.
179. Olive, P.L.; Vikse, C.M.; Durand, R.E. Hypoxic fractions measured in murine tumors and normal tissues using the comet assay. Int. J. Radiat. Oncol. Biol. Phys., 1994, 29, 487-91.
180. Choudhury, A.; Cuddihy, A.; Bristow, R.G. Radiation and new molecular agents part I: targeting ATM-ATR checkpoints, DNA repair, and the proteasome. Semin. Radiat. Oncol., 2006, 16, 51-8.
181. Bristow, R.G.; Ozcelik, H.; Jalali, F.; Chan, N.; Vesprini, D. Homologous recombination and prostate cancer: a model for novel DNA repair targets and therapies. Radiother. Oncol., 2007, 83, 220-30.
182. Hopkins, A.L.; Groom, C.R. The druggable genome. Nat. Rev. Drug Discov., 2002, 1, 727-30.
183. Abraham, R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev., 2001, 15, 2177-96.
184. Shiloh, Y. ATM and ATR: networking cellular responses to DNA damage. Curr. Opin. Genet. Dev., 2001, 11, 71-7.
185. Brown, E.J.; Baltimore, D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev., 2003, 17, 615-28.
186. Matsuoka, S.; Ballif, B.A.; Smogorzewska, A.; McDonald, E.R., III; Hurov, K.E.; Luo, J.; Bakalarski, C.E.; Zhao, Z.; Solimini, N.; Lerenthal, Y.; Shiloh, Y.; Gygi, S.P.; Elledge, S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science, 2007, 316, 1160-6.
187. Hickson, I.; Zhao, Y.; Richardson, C.J.; Green, S.J.; Martin, N.M.; Orr, A.I.; Reaper, P.M.; Jackson, S.P.; Curtin, N.J.; Smith, G.C. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res., 2004, 64, 9152-9.
188. Rainey, M.D.; Charlton, M.E.; Stanton, R.V.; Kastan, M.B. Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation. Cancer Res., 2008, 68, 7466-74.
189. Lord, C.J.; Garrett, M.D.; Ashworth, A. Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Clin. Cancer Res., 2006, 12, 4463-8.
190. Sarkaria, J.N.; Tibbetts, R.S.; Busby, E.C.; Kennedy, A.P.; Hill, D.E.; Abraham, R.T. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res., 1998, 58, 4375-82.
191. Izzard, R.A.; Jackson, S.P.; Smith, G.C. Competitive and noncompetitive inhibition of the DNA-dependent protein kinase. Cancer Res., 1999, 59, 2581-6.
192. Block, W.D.; Merkle, D.; Meek, K.; Lees-Miller, S.P. Selective inhibition of the DNA-dependent protein kinase (DNA-PK) by the radiosensitizing agent caffeine. Nucleic Acids Res., 2004, 32, 1967-72.
193. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci., 2008, 99, 1734-40.
194. Walker, E.H.; Pacold, M.E.; Perisic, O.; Stephens, L.; Hawkins, P.T.; Wymann, M.P.; Williams, R.L. Structural determinants of phosphoinositide 3-kinase inhibition by wortmannin, LY294002, quercetin, myricetin, and staurosporine. Mol. Cell, 2000, 6, 909-19.
195. Wymann, M.P.; Bulgarelli-Leva, G.; Zvelebil, M.J.; Pirola, L.; Vanhaesebroeck, B.; Waterfield, M.D.; Panayotou, G. Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction. Mol. Cell Biol., 1996, 16, 1722-33.
196. Sanchez-Perez, I. DNA repair inhibitors in cancer treatment. Clin. Transl. Oncol., 2006, 8, 642-6.
197. Nishida, H.; Tatewaki, N.; Nakajima, Y.; Magara, T.; Ko, K.M.; Hamamori, Y.; Konishi, T. Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response. Nucleic Acids Res., 2009, 37, 5678-89.
198. Li, L.; Lu, Q.; Shen, Y.; Hu, X. Schisandrin B enhances doxorubicin-induced apoptosis of cancer cells but not normal cells. Biochem. Pharmacol., 2006, 71, 584-95.
199. Hollick, J.J.; Golding, B.T.; Hardcastle, I.R.; Martin, N.; Richardson, C.; Rigoreau, L.J.; Smith, G.C.; Griffin, R.J. 2,6-disubstituted pyran-4-one and thiopyran-4-one inhibitors of DNA-Dependent protein kinase (DNA-PK). Bioorg. Med. Chem. Lett., 2003, 13, 3083-6.
200. Ismail, I.H.; Martensson, S.; Moshinsky, D.; Rice, A.; Tang, C.; Howlett, A.; McMahon, G.; Hammarsten, O. SU11752 inhibits the DNA-dependent protein kinase and DNA double-strand break repair resulting in ionizing radiation sensitization. Oncogene, 2004, 23, 873-82.
201. Leahy, J.J.; Golding, B.T.; Griffin, R.J.; Hardcastle, I.R.; Richardson, C.; Rigoreau, L.; Smith, G.C. Identification of a highly potent and selective DNA-dependent protein kinase (DNA-PK) inhibitor (NU7441) by screening of chromenone libraries. Bioorg. Med. Chem. Lett., 2004, 14, 6083-7.
202. Willmore, E.; de Caux, S.; Sunter, N.J.; Tilby, M.J.; Jackson, G.H.; Austin, C.A.; Durkacz, B.W. A novel DNA-dependent protein kinase inhibitor, NU7026, potentiates the cytotoxicity of topoisomerase II poisons used in the treatment of leukemia. Blood, 2004, 103, 4659-65.
203. Shinohara, E.T.; Geng, L.; Tan, J.; Chen, H.; Shir, Y.; Edwards, E.; Halbrook, J.; Kesicki, E.A.; Kashishian, A.; Hallahan, D.E. DNA-dependent protein kinase is a molecular target for the development of noncytotoxic radiation-sensitizing drugs. Cancer Res., 2005, 65, 4987-92.
204. Salles, B.; Calsou, P.; Frit, P.; Muller, C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol. Biol. (Paris), 2006, 54, 185-93.
205. Zhao, Y.; Thomas, H.D.; Batey, M.A.; Cowell, I.G.; Richardson, C.J.; Griffin, R.J.; Calvert, A.H.; Newell, D.R.; Smith, G.C.; Curtin, N.J. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res., 2006, 66, 5354-62.
206. Nutley, B.P.; Smith, N.F.; Hayes, A.; Kelland, L.R.; Brunton, L.; Golding, B.T.; Smith, G.C.; Martin, N.M.; Workman, P.; Raynaud, F.I. Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026. Br. J. Cancer, 2005, 93, 1011-8.
207. ClinicalTrials.gov. Available at http://www.clinicaltrials.gov. Accessed on October 2009.
208. Carey, N.; La Thangue, N.B. Histone deacetylase inhibitors: gathering pace. Curr. Opin. Pharmacol., 2006, 6, 369-75.
209. Mann, B.S.; Johnson, J.R.; Cohen, M.H.; Justice, R.; Pazdur, R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist, 2007, 12, 1247-52.
210. Prasad, K.N.; Sinha, P.K.; Ramanujam, M.; Sakamoto, A. Sodium ascorbate potentiates the growth inhibitory effect of certain agents on neuroblastoma cells in culture. Proc. Natl. Acad. Sci. U. S. A, 1979, 76, 829-32.
211. Nackerdien, Z.; Michie, J.; Bohm, L. Chromatin decondensed by acetylation shows an elevated radiation response. Radiat. Res., 1989, 117, 234-44.
212. Camphausen, K.; Scott, T.; Sproull, M.; Tofilon, P.J. Enhancement of xenograft tumor radiosensitivity by the histone deacetylase inhibitor MS-275 and correlation with histone hyperacetylation. Clin. Cancer Res., 2004, 10, 6066-71.
213. Camphausen, K.; Cerna, D.; Scott, T.; Sproull, M.; Burgan, W.E.; Cerra, M.A.; Fine, H.; Tofilon, P.J. Enhancement of in vitro and in vivo tumor cell radiosensitivity by valproic acid. Int. J. Cancer, 2005, 114, 380-6.
214. Geng, L.; Cuneo, K.C.; Fu, A.; Tu, T.; Atadja, P.W.; Hallahan, D.E. Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer. Cancer Res., 2006, 66, 11298-304.
215. Cuneo, K.C.; Fu, A.; Osusky, K.; Huamani, J.; Hallahan, D.E.; Geng, L. Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation. Anti-Cancer Drugs, 2007, 18, 793-800.
216. Johnstone, R.W.; Licht, J.D. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell, 2003, 4, 13-18.
217. Karagiannis, T.C.; Harikrishnan, K.N.; El Osta, A. The histone deacetylase inhibitor, Trichostatin A, enhances radiation sensitivity and accumulation of gammaH2A.X. Cancer Biol. Ther., 2005, 4, 787-93.
218. Munshi, A.; Tanaka, T.; Hobbs, M.L.; Tucker, S.L.; Richon, V.M.; Meyn, R.E. Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci. Mol. Cancer Ther., 2006, 5, 1967-74.
219. Zhang, Y.; Adachi, M.; Zou, H.; Hareyama, M.; Imai, K.; Shinomura, Y. Histone deacetylase inhibitors enhance phosphorylation of histone H2AX after ionizing radiation. Int. J. Radiat. Oncol. Biol. Phys., 2006, 65, 859-66.
220. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N.P.; Lewis, T.A.; Maglathin, R.L.; McLean, T.H.; Bochkarev, A.; Plotnikov, A.N.; Vedadi, M.; Arrowsmith, C.H. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem., 2008, 283, 11355-63.
221. Pharmacyclis. Available at http://www.pharmacyclics.com. Accessed on October 2009.
222. Banuelos, C.A.; Banath, J.P.; MacPhail, S.H.; Zhao, J.; Reitsema, T.; Olive, P.L. Radiosensitization by the histone deacetylase inhibitor PCI-24781. Clin. Cancer Res., 2007, 13, 6816-26.
223. Adimoolam, S.; Sirisawad, M.; Chen, J.; Thiemann, P.; Ford, J.M.; Buggy, J.J. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 19482-7.
224. Camphausen, K.;Tofilon, P.J. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J. Clin. Oncol., 2007, 25, 4051-6.
225. Balasubramanian, S.; Ramos, J.; Luo, W.; Sirisawad, M.; Verner, E.; Buggy, J.J. A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas. Leukemia, 2008, 22, 1026-34.
226. Chou, C.J.; Herman, D.; Gottesfeld, J.M. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J. Biol. Chem., 2008, 283, 35402-9.
227. Kao, J.; Milano, M.T.; Javaheri, A.; Garofalo, M.C.; Chmura, S.J.; Weichselbaum, R.R.; Kron, S.J. gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr. Cancer Drug Targets, 2006, 6, 197-205.
228. Janetka, J.W.; Ashwell, S. Checkpoint kinase inhibitors: a review of the patent literature. Expert. Opin. Ther. Pat., 2009, 19, 165-97.
229. Chen, Y.;Poon, R.Y. The multiple checkpoint functions of CHK1 and CHK2 in maintenance of genome stability. Front Biosci., 2008, 13, 5016-29.
230. Reinhardt, H.C.; Yaffe, M.B. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2. Curr. Opin. Cell Biol., 2009, 21, 245-55.
231. Busby, E.C.; Leistritz, D.F.; Abraham, R.T.; Karnitz, L.M.; Sarkaria, J.N. The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1. Cancer Res., 2000, 60, 2108-12.
232. Liang, Y.; Lin, S.Y.; Brunicardi, F.C.; Goss, J.; Li, K. DNA damage response pathways in tumor suppression and cancer treatment. World J. Surg., 2009, 33, 661-6.
233. Bunch, R.T.;Eastman, A. Enhancement of cisplatin-induced cytotoxicity by 7-hydroxystaurosporine (UCN-01), a new G2-checkpoint inhibitor. Clin. Cancer Res., 1996, 2, 791-7.
234. Wang, Q.; Fan, S.; Eastman, A.; Worland, P.J.; Sausville, E.A.; O'Connor, P.M. UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 1996, 88, 956-65.
235. Shao, R.G.; Cao, C.X.; Shimizu, T.; O'Connor, P.M.; Kohn, K.W.; Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 1997, 57, 4029-35.
236. Akinaga, S.; Nomura, K.; Gomi, K.; Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 1993, 32, 183-9.
237. Hsueh, C.T.; Kelsen, D.; Schwartz, G.K. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin. Cancer Res., 1998, 4, 2201-6.
238. Hirose, Y.; Berger, M.S.; Pieper, R.O. Abrogation of the Chk1-mediated G(2) checkpoint pathway potentiates temozolomide-induced toxicity in a p53-independent manner in human glioblastoma cells. Cancer Res., 2001, 61, 5843-9.
239. Shi, Z.; Azuma, A.; Sampath, D.; Li, Y.X.; Huang, P.; Plunkett, W. S-Phase arrest by nucleoside analogues and abrogation of survival without cell cycle progression by 7-hydroxystaurosporine. Cancer Res., 2001, 61, 1065-72.
240. Tse, A.N.; Carvajal, R.; Schwartz, G.K. Targeting checkpoint kinase 1 in cancer therapeutics. Clin. Cancer Res., 2007, 13, 1955-60.
241. Hosoya, N.;Miyagawa, K. Clinical importance of DNA repair inhibitors in cancer therapy. Magazine Europ. Med. Oncol. (MEMO), 2009, 2, 9-14.
242. Jackson, J.R.; Gilmartin, A.; Imburgia, C.; Winkler, J.D.; Marshall, L.A.; Roshak, A. An indolocarbazole inhibitor of human check-point kinase (Chk1) abrogates cell cycle arrest caused by DNA damage. Cancer Res., 2000, 60, 566-72.
243. Zhao, B.; Bower, M.J.; McDevitt, P.J.; Zhao, H.; Davis, S.T.; Johanson, K.O.; Green, S.M.; Concha, N.O.; Zhou, B.B. Structural basis for Chk1 inhibition by UCN-01. J. Biol. Chem., 2002, 277, 46609-15.
244. Kohn, E.A.; Yoo, C.J.; Eastman, A. The protein kinase C inhibitor Go6976 is a potent inhibitor of DNA damage-induced S and G2 cell cycle checkpoints. Cancer Res., 2003, 63, 31-5.
245. Jiang, X.; Zhao, B.; Britton, R.; Lim, L.Y.; Leong, D.; Sanghera, J.S.; Zhou, B.B.; Piers, E.; Andersen, R.J.; Roberge, M. Inhibition of Chk1 by the G2 DNA damage checkpoint inhibitor isogranulatimide. Mol. Cancer Ther., 2004, 3, 1221-7.
246. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther., 2004, 3, 513-9.
247. Collins, I.; Garrett, M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol., 2005, 5, 366-73.
248. Zhou, B.B.; Sausville, E.A. Drug discovery targeting Chk1 and Chk2 kinases. Prog. Cell Cycle Res., 2003, 5, 413-21.
249. Parsels, L.A.; Parsels, J.D.; Booth, R.J.; Denny, W.A.; Kraker, A.J.; Maybaum, J. The small-molecule chk1 inhibitor, PD-321852, causes synergistic depletion of chk1 protein and clonogenic death when combined with gemcitabine in colorectal and pancreatic tumor cells. Proc. Amer. Assoc. Cancer Res., 2006, 47, 1154.
250. Ashwell, S.; Janetka, J.W.; Zabludoff, S. Keeping checkpoint kinases in line: new selective inhibitors in clinical trials. Expert. Opin. Investig. Drugs, 2008, 17, 1331-40.
251. Zabludoff, S.D.; Deng, C.; Grondine, M.R.; Sheehy, A.M.; Ashwell, S.; Caleb, B.L.; Green, S.; Haye, H.R.; Horn, C.L.; Janetka, J.W.; Liu, D.; Mouchet, E.; Ready, S.; Rosenthal, J.L.; Queva, C.; Schwartz, G.K.; Taylor, K.J.; Tse, A.N.; Walker, G.E.; White, A.M. AZD7762, a novel checkpoint kinase inhibitor, drives check-point abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther., 2008, 7, 2955-66.
252. Parsels, L.A.; Morgan, M.A.; Tanska, D.M.; Parsels, J.D.; Palmer, B.D.; Booth, R.J.; Denny, W.A.; Canman, C.E.; Kraker, A.J.; Lawrence, T.S.; Maybaum, J. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol. Cancer Ther., 2009, 8, 45-54.
253. Sorensen, C.S.; Syljuasen, R.G.; Falck, J.; Schroeder, T.; Ronnstrand, L.; Khanna, K.K.; Zhou, B.B.; Bartek, J.; Lukas, J. Chk1 regulates the S phase checkpoint by coupling the physiological turnover and ionizing radiation-induced accelerated proteolysis of Cdc25A. Cancer Cell, 2003, 3, 247-58.
254. Syljuasen, R.G.; Sorensen, C.S.; Nylandsted, J.; Lukas, C.; Lukas, J.; Bartek, J. Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing Radiation. Cancer Res., 2004, 64, 9035-40.
255. Wang, G.T.; Li, G.; Mantei, R.A.; Chen, Z.; Kovar, P.; Gu, W.; Xiao, Z.; Zhang, H.; Sham, H.L.; Sowin, T.; Rosenberg, S.H.; Lin, N.H. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities. J. Med. Chem., 2005, 48, 3118-21.
256. Lin, N.H.; Xia, P.; Kovar, P.; Park, C.; Chen, Z.; Zhang, H.; Rosenberg, S.H.; Sham, H.L. Synthesis and biological evaluation of 3-ethylidene-1,3-dihydro-indol-2-ones as novel checkpoint 1 inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 421-6.
257. Keegan, K.; Kesicki, E.A.; Gaudino, J.J.; Cook, A.W.; Cowen, S.D.; Gurgess, L.E.WO 02/070494, 2002.
258. Boyle, R.G.; Imogai, H.J.; Cherry D.WO 03/101444, 2003.
259. Li, G.; Li, Q.; Li, T.; Lin, N.H.; Mantei, R.A.; Sham, H.L.; Wang, G.T.U.S. 034,038, 2004.
260. Li, G.; Hasvold, L.A.; Tao, Z.F.; Wang, G.T.; Gwaltney, S.L.; Patel, J.; Kovar, P.; Credo, R.B.; Chen, Z.; Zhang, H.; Park, C.; Sham, H.L.; Sowin, T.; Rosenberg, S.H.; Lin, N.H. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors. Bioorg. Med. Chem. Lett., 2006, 16, 2293-8.
261. Sharma, V.;Tepe, J.J. Potent inhibition of checkpoint kinase activity by a hymenialdisine-derived indoloazepine. Bioorg. Med. Chem. Lett., 2004, 14, 4319-21.
262. Arienti, K.L.; Brunmark, A.; Axe, F.U.; McClure, K.; Lee, A.; Blevitt, J.; Neff, D.K.; Huang, L.; Crawford, S.; Pandit, C.R.; Karlsson, L.; Breitenbucher, J.G. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J. Med. Chem., 2005, 48, 1873-85.
263. Lokesh, G.L.; Muralidhara, B.K.; Negi, S.S.; Natarajan, A. Thermodynamics of phosphopeptide tethering to BRCT: the structural minima for inhibitor design. J. Am. Chem. Soc., 2007, 129, 10658-9.
264. Simeonov, A.; Yasgar, A.; Jadhav, A.; Lokesh, G.L.; Klumpp, C.; Michael, S.; Austin, C.P.; Natarajan, A.; Inglese, J. Dualfluorophore quantitative high-throughput screen for inhibitors of BRCT-phosphoprotein interaction. Anal. Biochem., 2008, 375, 60-70.
265. Hartwell, L.H.; Szankasi, P.; Roberts, C.J.; Murray, A.W.; Friend, S.H. Integrating genetic approaches into the discovery of anticancer drugs. Science, 1997, 278, 1064-8.
266. Garber, K. Running interference: pace picks up on synthetic lethality research. J. Natl. Cancer Inst., 2004, 96, 982-3.
267. Kaelin, W.G., Jr. The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer, 2005, 5, 689-98.
268. Bryant, H.E.; Schultz, N.; Thomas, H.D.; Parker, K.M.; Flower, D.; Lopez, E.; Kyle, S.; Meuth, M.; Curtin, N.J.; Helleday, T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 2005, 434, 913-7.
269. Farmer, H.; McCabe, N.; Lord, C.J.; Tutt, A.N.; Johnson, D.A.; Richardson, T.B.; Santarosa, M.; Dillon, K.J.; Hickson, I.; Knights, C.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 2005, 434, 917-21.
270. Ame, J.C.; Spenlehauer, C.; de Murcia, G. The PARP superfamily. Bioessays, 2004, 26, 882-93.
271. Otto, H.; Reche, P.A.; Bazan, F.; Dittmar, K.; Haag, F.; Koch-Nolte, F. In silico characterization of the family of PARP-like poly(ADP-ribosyl)transferases (pARTs). BMC. Genomics, 2005, 6, 139.
272. Gagne, J.P.; Hendzel, M.J.; Droit, A.; Poirier, G.G. The expanding role of poly(ADP-ribose) metabolism: current challenges and new perspectives. Curr. Opin. Cell Biol., 2006, 18, 145-51.
273. Hassa, P.O.;Hottiger, M.O. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front. Biosci., 2008, 13, 3046-82.
274. Dantzer, F.; Ame, J.C.; Schreiber, V.; Nakamura, J.; Menissier-de Murcia, J.; de Murcia, G. Poly(ADP-ribose) polymerase-1 activation during DNA damage and repair. Methods Enzymol., 2006, 409, 493-510.
275. Zaremba, T.;Curtin, N.J. PARP inhibitor development for systemic cancer targeting. Anticancer Agents Med. Chem., 2007, 7, 515-23.
276. Dantzer, F.; de La, R.G.; Menissier-de Murcia, J.; Hostomsky, Z.; de Murcia, G.; Schreiber, V. Base excision repair is impaired in mammalian cells lacking Poly(ADP-ribose) polymerase-1. Biochemistry, 2000, 39, 7559-69.
277. Peralta-Leal, A.; Rodriguez, M.I.; Oliver, F.J. Poly(ADP-ribose)polymerase-1 (PARP-1) in carcinogenesis: Potential role of PARP inhibitors in cancer treatment. Clin. Transl.Oncol., 2008, 10, 318-23.
278. Woodhouse, B.C.; Dianova, I.I.; Parsons, J.L.; Dianov, G.L. Poly(ADP-ribose) polymerase-1 modulates DNA repair capacity and prevents formation of DNA double strand breaks. Dna Repair, 2008, 7, 932-40.
279. Virag, L.; Szabo, C. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev., 2002, 54, 375-429.
280. Southan, G.J.; Szabo, C. Poly(ADP-ribose) polymerase inhibitors. Curr. Med. Chem., 2003, 10, 321-40.
281. Miknyoczki, S.J.; Jones-Bolin, S.; Pritchard, S.; Hunter, K.; Zhao, H.; Wan, W.; Ator, M.; Bihovsky, R.; Hudkins, R.; Chatterjee, S.; Klein-Szanto, A.; Dionne, C.; Ruggeri, B. Chemopotentiation of temozolomide, irinotecan, and cisplatin activity by CEP-6800, a poly(ADP-ribose) polymerase inhibitor. Mol. Cancer Ther., 2003, 2, 371-82.
282. Calabrese, C.R.; Almassy, R.; Barton, S.; Batey, M.A.; Calvert, A.H.; Canan-Koch, S.; Durkacz, B.W.; Hostomsky, Z.; Kumpf, R.A.; Kyle, S.; Li, J.; Maegley, K.; Newell, D.R.; Notarianni, E.; Stratford, I.J.; Skalitzky, D.; Thomas, H.D.; Wang, L.Z.; Webber, S.E.; Williams, K.J.; Curtin, N.J. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J. Natl. Cancer Inst., 2004, 96, 56-67.
283. Curtin, N.J. PARP inhibitors for cancer therapy. Expert Rev. Mol. Med., 2005, 7, 1-20.
284. Miknyoczki, S.; Chang, H.; Grobelny, J.; Pritchard, S.; Worrell, C.; McGann, N.; Ator, M.; Husten, J.; Deibold, J.; Hudkins, R.; Zulli, A.; Parchment, R.; Ruggeri, B. The selective poly(ADP-ribose) polymerase-1(2) inhibitor, CEP-8983, increases the sensitivity of chemoresistant tumor cells to temozolomide and irinotecan but does not potentiate myelotoxicity. Mol. Cancer Ther., 2007, 6, 2290-302.
285. Ratnam, K.; Low, J.A. Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology. Clin. Cancer Res., 2007, 13, 1383-8.
286. Ashworth, A. Drug resistance caused by reversion mutation. Cancer Res., 2008, 68, 10021-3.
287. Tan, D.S.; Marchio, C.; Reis-Filho, J.S. Hereditary breast cancer: from molecular pathology to tailored therapies. J. Clin. Pathol., 2008, 61, 1073-82.
288. Chalmers, A.J. The potential role and application of PARP inhibitors in cancer treatment. Br. Med. Bull., 2009, 89, 23-40.
289. Plummer, E.R.; Middleton, M.R.; Jones, C.; Olsen, A.; Hickson, I.; McHugh, P.; Margison, G.P.; McGown, G.; Thorncroft, M.; Watson, A.J.; Boddy, A.V.; Calvert, A.H.; Harris, A.L.; Newell, D.R.; Curtin, N.J. Temozolomide pharmacodynamics in patients with metastatic melanoma: dna damage and activity of repair enzymes O6-alkylguanine alkyltransferase and poly(ADP-ribose) polymerase-1. Clin. Cancer Res., 2005, 11, 3402-9.
290. Plummer, E.R. Inhibition of poly(ADP-ribose) polymerase in cancer. Curr. Opin. Pharmacol., 2006, 6, 364-8.
291. Plummer, R.; Jones, C.; Middleton, M.; Wilson, R.; Evans, J.; Olsen, A.; Curtin, N.; Boddy, A.; McHugh, P.; Newell, D.; Harris, A.; Johnson, P.; Steinfeldt, H.; Dewji, R.; Wang, D.; Robson, L.; Calvert, H. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res., 2008, 14, 7917-23.
292. de Bono, J.; Boss, D.; Fong, P.; Roelvink, M.; Yap, T.; Tutt, A.; Mortimer, P.; O'Connor, M.; Schellens, J.H.; Kaye, S. First in human phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436 (KU), a small molecule inhibitor of poly ADP-RIBOSE polymerase (PARP) in cancer patients (P), including BRCA 1/2 mutation carriers. Ann. Oncol., 2007, 18, 26-7.
293. Tuma, R.S. Combining carefully selected drug, patient genetics may lead to total tumor death. J. Natl. Cancer Inst., 2007, 99, 1505-6, 1509.
294. Jones, P.; Altamura, S.; Boueres, J.; Ferrigno, F.; Fonsi, M.; Giomini, C.; Lamartina, S.; Monteagudo, E.; Ontoria, J.M.; Orsale, M.V.; Palumbi, M.C.; Pesci, S.; Roscilli, G.; Scarpelli, R.; Schultz-Fademrecht, C.; Toniatti, C.; Rowley, M. Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor effica-cious in BRCA-1 and -2 mutant tumors. J. Med. Chem., 2009, 52, 7170-85.
295. Drew, Y.; Plummer, R. PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist. Updat., 2009, 12, 153-6.
296. Champoux, J.J. DNA topoisomerases: structure, function, and mechanism. Annu. Rev. Biochem., 2001, 70, 369-413.
297. Treszezamsky, A.D.; Kachnic, L.A.; Feng, Z.H.; Zhang, J.R.; Tokadjian, C.; Powell, S.N. BRCA1-and BRCA2-deficient cells are sensitive to etoposide-induced DNA double-strand breaks via topoisomerase II. Cancer Res., 2007, 67, 7078-81.
298. Chemo.care. Available at www.chemocare.com/bio/etoposide.asp. Accessed on October 2009.
299. Chen, G.L.; Yang, L.; Rowe, T.C.; Halligan, B.D.; Tewey, K.M.; Liu, L.F. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem., 1984, 259, 13560-6.
300. Bhattacharyya, A.; Ear, U.S.; Koller, B.H.; Weichselbaum, R.R.; Bishop, D.K. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J. Biol. Chem., 2000, 275, 23899-903.
301. Howlett, N.G.; Taniguchi, T.; Olson, S.; Cox, B.; Waisfisz, Q.; Die-Smulders, C.; Persky, N.; Grompe, M.; Joenje, H.; Pals, G.; Ikeda, H.; Fox, E.A.; D'Andrea, A.D. Biallelic inactivation of BRCA2 in Fanconi anemia. Science, 2002, 297, 606-9.
302. Kraakman-van der Zwet, M.; Overkamp, W.J.; van Lange, R.E.; Essers, J.; Duijn-Goedhart, A.; Wiggers, I.; Swaminathan, S.; van Buul, P.P.; Errami, A.; Tan, R.T.; Jaspers, N.G.; Sharan, S.K.; Kanaar, R.; Zdzienicka, M.Z. Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions. Mol. Cell Biol., 2002, 22, 669-79.
303. Tutt, A.N.; Lord, C.J.; McCabe, N.; Farmer, H.; Turner, N.; Martin, N.M.; Jackson, S.P.; Smith, G.C.; Ashworth, A. Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer. Cold Spring Harb. Symp. Quant. Biol., 2005, 70, 139-48.
304. Evers, B.; Schut, E.; van der, B.E.; Braumuller, T.M.; Egan, D.A.; Holstege, H.; Edser, P.; Adams, D.J.; Wade-Martins, R.; Bouwman, P.; Jonkers, J. A high-throughput pharmaceutical screen identifies compounds with specific toxicity against BRCA2-deficient tumors. Clin. Cancer Res., 2010, 16, 99-108.
305. Tutt, A.; Bertwistle, D.; Valentine, J.; Gabriel, A.; Swift, S.; Ross, G.; Griffin, C.; Thacker, J.; Ashworth, A. Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences. EMBO J., 2001, 20, 4704-16.
306. Tassone, P.; Tagliaferri, P.; Perricelli, A.; Blotta, S.; Quaresima, B.; Martelli, M.L.; Goel, A.; Barbieri, V.; Costanzo, F.; Boland, C.R.; Venuta, S. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br. J. Cancer, 2003, 88, 1285-91.
307. Torrisi, R.; Balduzzi, A.; Ghisini, R.; Rocca, A.; Bottiglieri, L.; Giovanardi, F.; Veronesi, P.; Luini, A.; Orlando, L.; Viale, G.; Goldhirsch, A.; Colleoni, M. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother. Pharmacol., 2008, 62, 667-72.
308. Hoadley, K.A.; Weigman, V.J.; Fan, C.; Sawyer, L.R.; He, X.; Troester, M.A.; Sartor, C.I.; Rieger-House, T.; Bernard, P.S.; Carey, L.A.; Perou, C.M. EGFR associated expression profiles vary with breast tumor subtype. BMC. Genom., 2007, 8, 258.
309. Chia, S.K.; Speers, C.H.; D'yachkova, Y.; Kang, A.; Malfair-Taylor, S.; Barnett, J.; Coldman, A.; Gelmon, K.A.; O'Reilly, S.E.; Olivotto, I.A. The impact of new chemotherapeutic and agents on survival in a population-based of women with metastatic breast cancer hormone cohort. Cancer, 2007, 110, 973-9.
310. D'Incalci, M.; Erba, E.; Damia, G.; Galliera, E.; Carrassa, L.; Marchini, S.; Mantovani, R.; Tognon, G.; Fruscio, R.; Jimeno, J.; Faircloth, G.T. Unique features of the mode of action of ET-743. Oncologist, 2002, 7, 210-6.
311. D'Incalci, M.; Colombo, T.; Ubezio, P.; Nicoletti, I.; Giavazzi, R.; Erba, E.; Ferrarese, L.; Meco, D.; Riccardi, R.; Sessa, C.; Cavallini, E.; Jimeno, J.; Faircloth, G.T. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur. J. Cancer, 2003, 39, 1920-6.
312. Demetri, G.D. ET-743: the US experience in sarcomas of soft tissues. Anticancer Drugs, 2002, 13 Suppl 1, S7-S9.
313. D'Incalci, M.; Jimeno, J. Preclinical and clinical results with the natural marine product ET-743. Expert Opin. Investig. Drugs, 2003, 12, 1843-53.
314. Le Cesne, A.; Blay, J.Y.; Judson, I.; van Oosterom, A.; Verweij, J.; Radford, J.; Lorigan, P.; Rodenhuis, S.; Ray-Coquard, I.; Bonvalot, S.; Collin, F.; Jimeno, J.; Di Paola, E.; Van Glabbeke, M.; Nielsen, O.S. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol., 2005, 23, 576-84.
315. Herrero, A.B.; Martin-Castellanos, C.; Marco, E.; Gago, F.; Moreno, S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res., 2006, 66, 8155-62.
316. Soares, D.G.; Escargueil, A.E.; Poindessous, V.; Sarasin, A.; de Gramont, A.; Bonatto, D.; Henriques, J.A.P.; Larsen, A.K. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 13062-7.
317. Liu, S.K.; Olive, P.L.; Bristow, R.G. Biomarkers for DNA DSB inhibitors and radiotherapy clinical trials. Cancer Metastasis Rev., 2008, 27, 445-58.
318. Gorbunova, V.;Seluanov, A. Making ends meet in old age: DSB repair and aging. Mech. Ageing Dev., 2005, 126, 621-8.
319. Judkins, T.; Hendrickson, B.C.; Deffenbaugh, A.M.; Scholl, T. Single nucleotide polymorphisms in clinical genetic testing: the characterization of the clinical significance of genetic variants and their application in clinical research for BRCA1. Mutat. Res., 2005, 573, 168-79.
320. Chenevix-Trench, G.; Healey, S.; Lakhani, S.; Waring, P.; Cummings, M.; Brinkworth, R.; Deffenbaugh, A.M.; Burbidge, L.A.; Pruss, D.; Judkins, T.; Scholl, T.; Bekessy, A.; Marsh, A.; Lovelock, P.; Wong, M.; Tesoriero, A.; Renard, H.; Southey, M.; Hopper, J.L.; Yannoukakos, K.; Brown, M.; Easton, D.; Tavtigian, S.V.; Goldgar, D.; Spurdle, A.B. Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res., 2006, 66, 2019-27.
321. Huyton, T.; Bates, P.A.; Zhang, X.; Sternberg, M.J.; Freemont, P.S. The BRCA1 C-terminal domain: structure and function. Mutat. Res., 2000, 460, 319-32.
322. Phelan, C.M.; Dapic, V.; Tice, B.; Favis, R.; Kwan, E.; Barany, F.; Manoukian, S.; Radice, P.; van der Luijt, R.B.; van Nesselrooij, B.P.; Chenevix-Trench, G.; kConFab; Caldes, T.; de la, H.M.; Lindquist, S.; Tavtigian, S.V.; Goldgar, D.; Borg, A.; Narod, S.A.; Monteiro, A.N. Classification of BRCA1 missense variants of unknown clinical significance. J. Med. Genet., 2005, 42, 138-46.
323. Selleck. Available at http://www.selleckchem.com/. Accessed on October 2009.
324. Daniel, R.A.; Rozanska, A.L.; Thomas, H.D.; Mulligan, E.A.; Drew, Y.; Castelbuono, D.J.; Hostomsky, Z.; Plummer, E.R.; Boddy, A.; Tweddle, D.A.; Curtin, N.J.; Clifford, S.C. Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin. Cancer Res., 2009, 15, 1241-9.
325. Mante, S.; Minneman, K.P. Caffeine Inhibits Forskolin-Stimulated Cyclic-Amp Accumulation in Rat-Brain. Eur. J. Pharmacol., 1990, 175, 203-5.
326. Cortez, D. Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM-and Rad3-related (ATR) protein kinases. J. Biol. Chem., 2003, 278, 39-45.
327. Sarkaria, J.N.; Busby, E.C.; Tibbetts, R.S.; Roos, P.; Taya, Y.; Karnitz, L.M.; Abraham, R.T. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res., 1999, 59, 4375-82.
328. Foukas, L.C.; Daniele, N.; Ktori, C.; Anderson, K.E.; Jensen, J.; Shepherd, P.R. Direct effects of caffeine and theophylline on p110 delta and other phosphoinositide 3-kinases -Differential effects on lipid kinase and protein kinase activities. J. Biol. Chem., 2002, 277, 37124-30.
329. National Cancer Institute. Available at http:// www.cancer.gov. Accessed on October 2009.
330. Sorensen, C.S.; Syljuasen, R.G.; Lukas, J.; Bartek, J. ATR, claspin and the Rad9-Rad1-Hus1 complex regulate Chk1 and Cdc25A in the absence of DNA damage. Cell Cycle, 2004, 3, 941-5.
331. Kashishian, A.; Douangpanya, H.; Clark, D.; Schlachter, S.T.; Eary, C.T.; Schiro, J.G.; Huang, H.; Burgess, L.E.; Kesicki, E.A.; Halbrook, J. DNA-dependent protein kinase inhibitors as drug can-didates for the treatment of cancer. Mol. Cancer Ther., 2003, 2, 1257-64.
332. Shinohara, K.; Master, V.; Carroll, P.R.; Mcleod, D.G.; Beyer, D.C. Intermediate results of ferromagnetic thermal ablation for ra-diation failure local recurrence of prostate cancer. J. Urol., 2004, 171, 217.
333. Szabo, G.; Soos, P.; Mandera, S.; Heger, U.; Flechtenmacher, C.; Bahrle, S.; Seres, L.; Cziraki, A.; Gries, A.; Zsengeller, Z.; Vahl, C.F.; Hagl, S.; Szabo, C. INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. Shock, 2004, 21, 426-32.
334. Morrow, D.A.; Brickman, C.M.; Murphy, S.A.; Baran, K.; Krakover, R.; Dauerman, H.; Kumar, S.; Slomowitz, N.; Grip, L.; McCabe, C.H.; Salzman, A.L. A randomized, placebo-controlled trial to evaluate the tolerability, safety, pharmacokinetics, and pharmacodynamics of a potent inhibitor of poly(ADP-ribose) polymerase (INO-1001) in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of the TIMI 37 trial. J. Thromb. Thrombolysis., 2009, 27, 359-64.
335. http://www.scbt.com. Accessed on October 2009.
336. Fong, P.C.; Spicer, J.; Reade, S.; Reid, A.; Vidal, L.; Schellens, J.H.; Tutt, A.; Harris, P.A.; Kaye, S.; De Bono, J.S. Phase I pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of a small molecule inhibitor of poly ADP-ribose polymerase (PARP), KU-0059436 (Ku) in patients (p) with advanced tumours. J. Clin. Oncol., 2006, 24, 126S.
337. Dungey, F.A.; Loser, D.A.; Chalmers, A.J. Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(Adp-Ribose) Polymerase: Mechanisms and Therapeutic Potential. Int. J. Radiat. Oncol. Biol. Phys., 2008, 72, 1188-97.
338. Take, Y.; Kumano, M.; Hamano, Y.; Fukatsu, H.; Teraoka, H.; Nishimura, S.; Okuyama, A. Ok-1035, A Selective Inhibitor of Dna-Dependent Protein-Kinase. Biochem. Biophys. Res. Commun., 1995, 215, 41-7.
339. Stockley, M.; Clegg, W.; Fontana, G.; Golding, B.T.; Martin, N.; Rigoreau, L.J.M.; Smith, G.C.M.; Griffin, R.J. Synthesis, crystal structure determination, and biological properties of the DNA-dependent protein kinase (DNA-PK) inhibitor 3-cyano-6-hydra-zonomethyl-5-(4-pyridyl)pyrid-[1H]-2-one (OK-1035). Bioorg. Med. Chem. Lett., 2001, 11, 2837-41.
340. Blasina, A.; Hallin, J.; Chen, E.H.; Arango, M.E.; Kraynov, E.; Register, J.; Grant, S.; Ninkovic, S.; Chen, P.; Nichols, T.; O'Connor, P.; Anderes, K. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther., 2008, 7, 2394-04.
341. Peixoto, P.;Lansiaux, A. Histone-deacetylases inhibitors: from TSA to SAHA. Bull. Cancer, 2006, 93, 27-36.
342. Tocris Bioscence. Available at http://www.tocris.com. Accessed on October 2009.
343. Woo, S.H.; Frechette, S.; Abou, K.E.; Bouchain, G.; Vaisburg, A.; Bernstein, N.; Moradei, O.; Leit, S.; Allan, M.; Fournel, M.; Trachy-Bourget, M.C.; Li, Z.; Besterman, J.M.; Delorme, D. Structurally simple trichostatin A-like straight chain hydroxamates as potent histone deacetylase inhibitors. J. Med. Chem., 2002, 45, 2877-85.
344. Hu, E.D.; Dul, E.; Sung, C.M.; Chen, Z.X.; Kirkpatrick, R.; Zhang, G.F.; Johanson, K.; Liu, R.G.; Lago, A.; Hofmann, G.; Macarron, R.; los Frailes, M.; Perez, P.; Krawiec, J.; Winkler, J.; Jaye, M. Identification of novel isoform-selective inhibitors within class I histone deacetylases. J. Pharmacol. Exp. Ther., 2003, 307, 720-8.
345. Graves, P.R.; Yu, L.J.; Schwarz, J.K.; Gales, J.; Sausville, E.A.; O'Connor, P.M.; Piwnica-Worms, H. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J. Biol. Chem., 2000, 275, 5600-5.
346. Sato, S.; Fujita, N.; Tsuruo, T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene, 2002, 21, 1727-38.
347. Yu, Q.; La Rose, J.; Zhang, H.L.; Takemura, H.; Kohn, K.W.; Pommier, Y. UCN-01 inhibits p53 up-regulation and abrogates gamma-radiation-induced G(2)-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res., 2002, 62, 5743-8.
348. Eikel, D.; Lampen, A.; Nau, H. Teratogenic effects mediated by inhibition of histone deacetylases: Evidence from quantitative structure activity relationships of 20 valproic acid derivatives. Chem. Res. Toxicol., 2006, 19, 272-8.
349. Durant, S.;Karran, P. Vanillins -a novel family of DNA-PK inhibitors. Nucleic Acids Res., 2003, 31, 5501-12.
350. Nakanishi, S.; Kakita, S.; Takahashi, I.; Kawahara, K.; Tsukuda, E.; Sano, T.; Yamada, K.; Yoshida, M.; Kase, H.; Matsuda, Y.; Hashimoto, Y.; Nonomura, Y. Wortmannin, A microbial product inhibitor of myosin light chain kinase. J. Biol. Chem., 1992, 267, 2157-63.
351. Stoyanova, S.; BulgarelliLeva, G.; Kirsch, C.; Hanck, T.; Klinger, R.; Wetzker, R.; Wymann, M.P. Lipid kinase and protein kinase activities of G-protein-coupled phosphoinositide 3-kinase gamma: Structure-activity analysis and interactions with wortmannin. Biochem. J., 1997, 324, 489-95.
352. Ihle, N.T.; Williams, R.; Chow, S.; Chew, W.; Berggren, M.I.; Paine-Murrieta, G.; Minion, D.J.; Halter, R.J.; Wipf, P.; Abraham, R.; Kirkpatrick, L.; Powis, G. Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling. Mol. Cancer Ther., 2004, 3, 763-72.
353. Ihle, N.T.; Paine-Murrieta, G.; Berggren, M.I.; Baker, A.; Tate, W.R.; Wipf, P.; Abraham, R.T.; Kirkpatrick, D.L.; Powis, G. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol. Cancer Ther., 2005, 4, 1349-57.
354. Knight, Z.A.; Gonzalez, B.; Feldman, M.E.; Zunder, E.R.; Goldenberg, D.D.; Williams, O.; Loewith, R.; Stokoe, D.; Balla, A.; Toth, B.; Balla, T.; Weiss, W.A.; Williams, R.L.; Shokat, K.M. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell, 2006, 125, 733-47.
355. Matthews, D.J.; Yakes, F.M.; Chen, J.; Tadano, M.; Bornheim, L.; Clary, D.O.; Tai, A.; Wagner, J.M.; Miller, N.; Kim, Y.D.; Robertson, S.; Murray, L.; Karnitz, L.M. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle, 2007, 6, 104-10.